69 results
8-K
EX-99.1
KA
Kineta Inc
5 Jan 24
Regulation FD Disclosure
4:30pm
Investor Relations & Business Development Experienced leadership team Craig Philips President Keith Baker Chief Financial Officer Pauline Kenny General
8-K
EX-99.2
KA
Kineta Inc
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
& Business Development Experienced leadership team Craig Philips President Keith Baker Chief Financial Officer Pauline Kenny General Counsel
KVA12123
8-K
EX-99.2
KA
Kineta Inc
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
Scientific Officer Jacques Bouchy EVP Investor Relations & Business Development Experienced leadership team Craig Philips President Keith Baker Chief
8-K
EX-99.1
aitljexyni8f5ux3mx
11 Aug 23
Regulation FD Disclosure
4:08pm
8-K
EX-99.1
6wkq3rqlurvnj4obzq
9 Jun 23
Submission of Matters to a Vote of Security Holders
9:00am
8-K
EX-99.1
l91ejeug4zi1x0 jf6
31 Mar 23
Regulation FD Disclosure
12:00am
8-K
lkvxuz tztmmmgk
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.5
nej0onhee w11bri28
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
425
e95or 1v2hfqdpk0
6 Dec 22
Business combination disclosure
4:04pm
8-K
EX-99.1
ydorekh
6 Dec 22
Regulation FD Disclosure
4:02pm
424B3
iw8dyv03jc5
10 Nov 22
Prospectus supplement
4:21pm
425
tzb k4d5vrn38cgp7w
26 Oct 22
Business combination disclosure
5:17pm
8-K
EX-99.1
av3xp7
26 Oct 22
Regulation FD Disclosure
5:14pm